PMID- 18081852
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20080211
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 17
IP  - 3
DP  - 2008 Mar
TI  - CD40 ligation during dendritic cell maturation reduces cell death and prevents 
      interleukin-10-induced regression to macrophage-like monocytes.
PG  - 177-87
AB  - Dendritic cells (DCs) have become popular candidates in cancer vaccination 
      because of their crucial role in inducing T-cell responses. However, clinical 
      studies greatly differ in their protocols for generating DCs and the efficacy in 
      treating established tumors needs to be improved. We systematically analyzed DCs 
      maturated by five different protocols for surface markers, the alloproliferative 
      T-cell response, the DC survival after cytokine deprivation, the stability of 
      surface markers under the influence of interleukin-10 (IL-10) and the DC cytokine 
      secretion pattern. Monocyte-derived DCs were maturated by CD40-ligand (CD40-L), 
      unmethylated cytosine-guanosine dinucleotides-oligodinucleotides (CpG-ODN), an 
      inflammatory cytokine cocktail (ICC), a combination of ICC and CD40-L, or ICC, 
      CD40-L and CpG-ODN. A high co-expression of DC maturation and costimulation 
      markers was found after treatment with ICC plus CD40-L (69.3 +/- 9.6% CD83/CD80 
      double positive staining) and correlated with a significantly increased cell 
      survival, a high expression of the antiapoptotic factor bcl-(XL), a stable 
      CD83(high)/CD14(low) expression under the influence of IL-10, and a strong 
      alloproliferative T-cell response. In conclusion, our data support the use of 
      maturation protocols containing ICC plus CD40-L in order to generate highly 
      mature, phenotypically stable, cell-death resistant, and T-cell stimulatory DCs 
      for clinical application in cancer patients.
FAU - Haenssle, Holger
AU  - Haenssle H
AD  - Department of Dermatology, Georg-August-University Goettingen, Goettingen, 
      Germany. h.haenssle@med.uni-goettingen.de
FAU - Buhl, Timo
AU  - Buhl T
FAU - Knudsen, Susanne
AU  - Knudsen S
FAU - Krueger, Ullrich
AU  - Krueger U
FAU - Rosenberger, Albert
AU  - Rosenberger A
FAU - Reich, Kristian
AU  - Reich K
FAU - Neumann, Christine
AU  - Neumann C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071213
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Antigens, CD)
RN  - 0 (CPG-oligonucleotide)
RN  - 0 (Cytokines)
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (bcl-X Protein)
RN  - 130068-27-8 (Interleukin-10)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Antigens, CD/metabolism
MH  - CD40 Ligand/*pharmacology
MH  - Cell Culture Techniques/*methods
MH  - Cell Death/*drug effects
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Cytokines/genetics/metabolism/*pharmacology
MH  - Dendritic Cells/cytology/*drug effects
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-10/genetics/metabolism/*pharmacology
MH  - Leukapheresis
MH  - Monocytes/cytology/metabolism
MH  - Oligodeoxyribonucleotides/*pharmacology
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - T-Lymphocytes/metabolism
MH  - bcl-X Protein/metabolism
EDAT- 2007/12/18 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/12/18 09:00
PHST- 2007/12/18 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/12/18 09:00 [entrez]
AID - EXD668 [pii]
AID - 10.1111/j.1600-0625.2007.00668.x [doi]
PST - ppublish
SO  - Exp Dermatol. 2008 Mar;17(3):177-87. doi: 10.1111/j.1600-0625.2007.00668.x. Epub 
      2007 Dec 13.